Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Thrombosis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Thrombosis
    Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty - (N Engl J Med)
    Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty - (N Engl J Med)
    Extended-Use Rivaroxaban Effectively Prevents Venous Thromboembolism After Hip Surgery - (DGNews)
    Drug-Eluting Stents May Decrease Repeat Revascularisation - (DGNews)
    International Panel Agrees on Guidelines for Preventing Thrombosis in Special Patient Groups - (DGNews)

    News archive

     Recent webcasts/CME - Thrombosis
    • Background: Prevention and Management of Venous Thromboembolism in Patients with Cancer: A Case-Based Approach
    • Case Study 1: 62-Year-Old Woman With Stage IV Breast Cancer and Repeated Courses of Chemotherapy
    • Case Study 2: 64-Year-Old Man With Stage III Colorectal Cancer Who Is Scheduled for Surgery
    • Long-Term Effects on Arterial Healing with DES
      Venous Thromboembolism and Acute Coronary Syndrome: Community Pharmacists' Key Position in the Continuum of Care

      Webcasts/CME archive

       Recent cases - Thrombosis
        Sigmoid Sinus Thrombosis Presenting with Posterior Alexia in a Patient with Behcet's Disease And Polycythaemia: A Case Report
        Left Atrial Giant Thrombus Infected by Escherichia Coli. Case Report
        Middle Bile Duct Cancer with Portal Vein Tumor Thrombus
        Pleural Mesothelioma and Venous Thrombosis: The Eosinophilia Link
        Elevated Maternal Lipoprotein (A) and Neonatal Renal Vein Thrombosis: A Case Report

        Cases archive
          




        my personal edition > thrombosis > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Herbal Supplement Ginseng Reduces Effects Of Warfarin

        CHICAGO, IL -- July 6, 2004 -- Researchers from the University of Chicago report in the July 6, 2004, issue of the Annals of Internal Medicine that ginseng, one of the best selling herbal supplements in the United States, interferes with warfarin, a drug commonly used to prevent blood clots.

        The researchers encourage anyone who takes both ginseng and warfarin, also known as Coumadin®, to notify his or her doctor and urged doctors to ask patients on warfarin if they are taking ginseng.

        "Warfarin has a narrow therapeutic index," said study author Chun-Su Yuan, M.D., Ph.D., "which means precise dosing is crucial."

        "With too small a dose," added Yuan, the Cyrus Tang Professor of Anesthesia & Critical Care and director of the Tang Center for Herbal Medicine Research at the University of Chicago, "the risk of clots increases, but too much can cause serious bleeding. So a substance, such as ginseng, that alters warfarin's effects, even slightly, can have significant consequences."

        The 'blood-thinner' warfarin, taken once a day by about 3 million people in the U.S., is used to prevent blood clots from forming or growing larger. It is often prescribed for patients with certain types of irregular heartbeat, those who have had a heart attack or undergone heart valve replacement surgery. It prevents the formation of substances that cause clots.

        Package inserts stress the importance of maintaining the proper dose. "It cannot be emphasized too strongly," notes the insert, "that treatment of each patient is a highly individualized matter. Warfarin sodium, a narrow therapeutic range drug, may be affected by factors such as other drugs and dietary Vitamin K. Dosage should be controlled by periodic determinations of prothrombin time," a measure of clotting speed.

        Yuan's team studied 20 healthy volunteer subjects for four weeks. All subjects received 5 mg a day of warfarin for three days during week one and again in week four. Beginning in week two, 12 subjects took two grams of powdered ginseng in capsules. The other eight volunteers received a placebo. The researchers monitored blood levels of warfarin and the clotting ability of the blood.

        They found that after two weeks, daily doses of ginseng significantly reduced the blood levels and the anti-clotting effects of warfarin.

        Since ginseng alone can promote bleeding and delay clot formation, the researchers were surprised to find that it reduced the anti-clotting effect of warfarin compared to those who took the placebo. They suspect that substances within ginseng may enhance the function of enzymes that break down warfarin, clearing it from the blood stream more rapidly.

        The National Institutes of Health and the Tang Center for Herbal Medicine Research funded this study. Additional authors include Gang Wei, Lucy Dey, Theodore Karrison, Linda Nahlik, Spring Maleckar, Kristen Kasza, Michael Ang-Lee and Jonathan Moss of the University of Chicago.


        SOURCE: University of Chicago Medical Center



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send